Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.
about
Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma : a meta-analysis of 37 trialsEvolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexityAmerican Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic CeTargeted treatments for multiple myeloma: specific role of carfilzomibEvolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted TherapiesA clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myelomaPharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study.Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability.Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma.High expression of endoplasmic reticulum chaperone grp94 is a novel molecular hallmark of malignant plasma cells in multiple myelomaTherapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myelomaSpecificity of Protein Covalent Modification by the Electrophilic Proteasome Inhibitor Carfilzomib in Human CellsIncidence and risk of hypertension in patients newly treated for multiple myeloma: a retrospective cohort studyCHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.Intersection of the Roles of Cytochrome P450 Enzymes with Xenobiotic and Endogenous Substrates: Relevance to Toxicity and Drug Interactions.Carfilzomib boosted combination therapy for relapsed multiple myelomaA practical review on carfilzomib in multiple myeloma.Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.Safety of proteasome inhibitors for treatment of multiple myeloma.Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple Myeloma.Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer.Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics.Phase I dose escalation study of high dose carfilzomib monotherapy for Japanese patients with relapsed or refractory multiple myeloma.'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors.Expression of possible targets for new proteasome inhibitors in diffuse large B-cell lymphoma.Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay.Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma.Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis.Cardiotoxicity with carfilzomib at doses greater than 27 mg/m(2): A case series.Inhibition of the Proteasome β2 Site Sensitizes Triple-Negative Breast Cancer Cells to β5 Inhibitors and Suppresses Nrf1 Activation.Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma.An overview of the role of carfilzomib in the treatment of multiple myeloma.Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells.Current Advances in Pharmacotherapy and Technology for Diabetic Retinopathy: A Systematic Review.Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response
P2860
Q26741620-91C8713A-F5F5-42F5-A7BB-A70ECC2D7941Q26771331-BB3B71AA-250D-4803-8A22-7380EB5AB392Q26782868-773A48A1-CFC7-4DD4-A437-E26C26D5C6C9Q26996524-E3D25FEA-D44D-46F8-A00D-ABB107B5B554Q27026478-C2C615AC-F2A0-4821-AC57-62AC5D344E6EQ28067148-84BD1B67-6D57-4468-9F34-60E6E7C16BB4Q33710330-D83A6D7C-DAEB-4AB9-8940-C6E9E67888A7Q34893956-671021E7-F588-490C-A45B-D27E11C76B02Q35571044-0DED08DA-4D8A-444A-AB7C-AD79366C612BQ35789280-4188F7B8-8299-4870-A560-31DEC4C9FF8FQ35895152-09B78EFC-3D32-403A-A1AD-36C053D40476Q35907767-84EC4C4D-679F-4E01-8894-B010A4577451Q36098363-F26462A5-EC96-40D1-84FD-B82F544A6E77Q36201429-BE19AA58-F526-4723-9FD2-F904E7FFEC7BQ37058114-DDA72F05-8B42-47FF-88FB-BB8FD2ED6564Q37627001-A8C0A4C5-7C94-4CA7-9B15-6625738A4DAFQ37652953-989F6491-5FA5-49DD-91EE-0FC7F014E4ADQ38740271-44D3AFCC-66B2-4A4E-91D2-B6B548E3823FQ38757067-52D982E8-8688-433B-A9FA-053E03037B85Q38989789-D0BE32C1-C27D-40F9-87C6-3F69086A4F15Q39007504-EF6BB7E3-2E08-4E45-836B-2760D853BDB3Q39124257-5885CD97-3CA3-440B-A9C5-299420E4F1ACQ39226762-CC877981-6A19-497E-ADD5-84355C78EFF7Q39234159-A3E35DA2-579F-4411-BF4F-B1B085CED2C0Q40083541-FE1029D8-FDAF-4FCD-B6E4-FCC8FFB55297Q40582501-78A73291-0BCC-466F-A942-4397B758DA0EQ40701267-D93486A6-EF8F-44FB-AAD1-DE8FFFBB3300Q41531584-C9D6AE41-1C97-4493-81A8-5AA14676A0C9Q42425704-F971889C-6525-4B76-B401-77674541CB2EQ47236245-D5D435F1-9D02-455F-A4CB-198A3507B568Q47980047-3CC8EBD3-F12E-4209-A763-D0C8A688E6BCQ47987649-E4AAC0CF-5AAB-4C75-A231-50D4C9505EDAQ48373422-E882FC18-5FE6-4E60-AD64-A85F5C53723DQ50035012-1EA49A4E-3535-4D5B-A7A7-58543F6D7A12Q51504147-17009590-B5DE-484B-A3EC-0AFB6F951E5CQ52632539-DED8A33A-4AC0-4B6A-B859-B84E3F0BA5BFQ58779410-02EB9770-5823-4F37-AB24-5EBBCFC4C68C
P2860
Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Phase I study of 30-minute inf ...... r refractory multiple myeloma.
@ast
Phase I study of 30-minute inf ...... r refractory multiple myeloma.
@en
type
label
Phase I study of 30-minute inf ...... r refractory multiple myeloma.
@ast
Phase I study of 30-minute inf ...... r refractory multiple myeloma.
@en
prefLabel
Phase I study of 30-minute inf ...... r refractory multiple myeloma.
@ast
Phase I study of 30-minute inf ...... r refractory multiple myeloma.
@en
P2093
P356
P1476
Phase I study of 30-minute inf ...... r refractory multiple myeloma.
@en
P2093
Ashraf Badros
David H Vesole
David S Siegel
Joseph R Holahan
Kyriakos P Papadopoulos
Naseem Zojwalla
Steven T Rosen
Zhengping Wang
P304
P356
10.1200/JCO.2013.52.3522
P407
P577
2014-09-15T00:00:00Z